Abstract: Disclosed herein are nanoparticles comprising one or more Human papillomavirus (HPV) antigen and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating a HPV infection or treating or preventing a disease or disorder associated therewith in a subject in need thereof, by administering the nanoparticles, or encoding nucleic acid molecules, to the subject.

Abstract: Provided are a method and apparatus for displaying active friend information, an electronic device, and a storage medium. The method for displaying the active friend information includes receiving an activity information checking instruction, where the activity information checking instruction is generated when a user triggers an entry control on a message page; and displaying an active friend list, where the active friend list displays activity information of an active friend of the user, and the active friend is a friend who is online in a recent preset time period. In this manner, a process of checking the active friend information is simplified and the time spent on checking the active friend information is shortened.

Abstract: A display substrate and a display device are provided. The display substrate includes a base substrate, at least one group of contact pads, a plurality of first light-emitting elements, a plurality of first pixel driving circuits, a plurality of connecting traces, a plurality of data lines and a plurality of leads. The display area includes a first display area and a second display area; the first light-emitting elements are located in the first display area; the first pixel driving circuits are located in the second display area; the leads are located in the first display area and the peripheral area, and connect the data lines and the at least one group of contact pads; orthographic projections of the first light-emitting elements on a substrate surface of the base substrate are at least partly overlapped with orthographic projections of the leads on the substrate surface of the base substrate.

Abstract: The present disclosure provides a magnetron sputtering apparatus, including a process chamber, a bias power supply assembly, and an excitation power supply assembly. The process chamber is provided with a base assembly and a bias guide assembly. A target is arranged at a top of the process chamber. The base assembly is arranged at a bottom of the process chamber and is configured to support a wafer carrier, drive the wafer carrier to move, and heat the wafer carrier. The bias guide assembly is arranged at the base assembly and configured to support the wafer carrier. The bias guide assembly is electrically in contact with the wafer carrier. The bias power supply assembly is electrically connected to the bias guide assembly and configured to apply a bias voltage to the wafer carrier through the bias guide assembly.

Abstract: Disclosed herein are nanoparticles comprising one or more SARS coronavirus 2 (SARS-CoV-2) Spike receptor binding domain (RBD) antigen and nucleic acid molecules encoding the same. Also disclosed herein is a method of treating a SARS-COV-2 infection or treating or preventing a disease or disorder associated therewith in a subject in need thereof, by administering the nanoparticles, or encoding nucleic acid molecules, to the subject.

Abstract: Disclosed is a base station comprising a base and a liquid path system disposed on the base. The liquid path system may comprise a first device and a second device. The first device may be configured to perform a first treatment on water to form a first liquid, and the second device is configured to perform a second treatment on water to form a second liquid. The second liquid may be different from the first liquid in temperature and/or composition. The first device can provide the first liquid with a first function for a cleaning robot, and the second device can provide a second liquid with a second function for the cleaning robot, so that the base station can provide a variety of liquids with different functions for the cleaning robot to meet different floors, different environments, and different user needs.

Abstract: Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a sequence that encodes an adjuvant polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence comprising a sequence that encodes an antigen from a virus or from a cancer. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker.

Abstract: Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a leader sequence or a pharmaceutically acceptable salt thereof; and a second nucleic acid sequence comprising a sequence that encodes a self-assembling polypeptide or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker. Also disclosed are pharmaceutical compositions comprising these compositions and methods of using the disclosed compositions.

Abstract: Disclosed herein are compositions and methods for post-translationally modifying synthetic biologics in vivo.